Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
High-risk Diffuse Large B-cell Lymphoma
Interventions
DRUG

Blinatumomab

Blinatumomab is administered as a continuous IV infusion.

Trial Locations (32)

1011

Research Site, Lausanne

2065

Research Site, St Leonards

2145

Research Site, Westmead

3000

Research Site, Leuven

3010

Research Site, Bern

3168

Research Site, Clayton

3220

Research Site, Geelong

4000

Research Site, Liège

6000

Research Site, Charleroi

6500

Research Site, Bellinzona

8091

Research Site, Zurich

10126

Research Site, Torino

10676

Research Site, Athens

11527

Research Site, Athens

13009

Research Site, Marseille

20162

Research Site, Milan

24127

Research Site, Bergamo

25123

Research Site, Brescia

30342

Research Site, Atlanta

33604

Research Site, Pessac

34295

Research Site, Montpellier

44195

Research Site, Cleveland

50134

Research Site, Florence

57010

Research Site, Thessaloniki

59037

Research Site, Lille

60153

Research Site, Maywood

69495

Research Site, Pierre-Bénite

75246

Research Site, Dallas

75475

Research Site, Paris

76038

Research Site, Rouen

90146

Research Site, Palermo

94010

Research Site, Créteil

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY